Table 1 Clinical and genetic details of the t(11;18)(q21;q21)-positive and -negative gastric MALT lymphomas
Case | Age | Sex | t(11;18) | Location of the MALT1 break point | FISH documented genetic aberrations a | Hp | Staging | Therapy b | Follow-up |
---|---|---|---|---|---|---|---|---|---|
LL31 | M | 52 | + | Intron 4 | − | + | I AE | Gastrectomy | CR |
LL53 | M | 52 | + | Intron 4 | − | − | NA | NA | NA |
LL57 | F | 68 | + | Intron 4 | − | + | IVc | Gastrectomy + CT | CR |
L87 | M | 54 | + | Intron 4 | − | + | I AE | Gastrectomy | CR |
LL29 | F | 26 | + | Intron 7 | − | + | I AE | Gastrectomy | CR |
LL51 | M | 52 | + | Intron 7 | − | − | I AE | Gastrectomy | Relapse in the lung 8 years after initial diagnosis with CR after secondary treatment |
LL27 | M | 46 | + | Intron 7 | − | + | I AE | Gastrectomy | Relapse in the stomach 1 year after initial diagnosis, with PR and SD after recurrent therapy (surg, RT, CT, Hp eradication) |
LL79 | M | 42 | + | Intron 7 | − | + | I AE | Gastrectomy | CR |
LL39 | F | 60 | + | Intron 8 | − | + | I AE | Gastrectomy | CR |
LL72 | M | 42 | + | Intron 8 | − | + | II | Gastrectomy + RT | CR |
LL52 | F | 47 | − | − | − | + | I AE | Gastrectomy | CR |
LL5 | F | 63 | − | − | Trisomy 3 and 18 | − | I AE | Gastrectomy | CR |
LL75 | F | 41 | − | − | Trisomy 3; MALT1 amplification | + | I AE | Gastrectomy | CR |
LL34 | F | 75 | − | − | − | + | I AE | Gastrectomy | CR |